This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy Study of LY2422347 to Treat Insomnia

This study has been completed.
Information provided by:
Eli Lilly and Company Identifier:
First received: November 28, 2005
Last updated: January 24, 2007
Last verified: January 2007
The purpose of this study is to determine whether a compound known as LY2422347 is effective in treating people diagnosed with primary insomnia (difficulty sleeping with no other significant contributing factor, such as depression).

Condition Intervention Phase
Sleep Initiation and Maintenance Disorders Drug: LY2422347 Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind Comparison of 5 mg of LY2422347, 15 mg of LY2422347, and Placebo in the Treatment of Patients With Primary Insomnia

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • The primary efficacy measure will be Wakening After Sleep Onset (WASO)

Secondary Outcome Measures:
  • Wake Time During Sleep (WTDS) and Wake Time After Sleep (WTAS)
  • improvement of daily subjective sleep quality at endpoint
  • reduction in the Number of Awakenings or Arousal Index and increase of time spent in Slow Wave Sleep (SWS) and various other parameters at endpoint as measured with PSG
  • Various characteristics of sleep and daytime functioning assessed with biweekly self-report questionnaires at endpoint
  • increase in subjective sleep efficiency at endpoint as assessed by the patient's daily diary
  • Clinician Global Impression of Improvement (CGI-I) score at endpoint
  • improvement at endpoint on the biweekly subjective assessment of physical role functioning, emotional role functioning, vitality, social functioning, and mental health using the Short Form-12
  • Safety and tolerability of LY2422347 compared with placebo

Estimated Enrollment: 400
Study Start Date: November 2005
Estimated Study Completion Date: November 2006

Ages Eligible for Study:   24 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • must have been diagnosed with primary insomnia
  • must not be significantly overweight
  • must be able to visit the study doctor's office once every 2 weeks for 8 weeks and willing to use a handheld electronic device as a sleep diary every day
  • must be able to read and speak in English and be able to see well enough to use the handheld electronic device
  • the patient's answer to the question "During the past month, how would you rate your sleep quality overall?" must be either "Very Bad" or "Fairly Bad"

Exclusion Criteria:

  • cannot have a clinically significant and/or uncontrolled condition or other significant ailment including restless leg syndrome (RLS) or periodic limb movement disorder (PLMD)
  • cannot have obstructive sleep apnea (OSA), or be considered by the study doctor to have probable OSA based upon patient history and physical examination
  • cannot be currently using antidepressants, antipsychotics, stimulants, antihistaminics, or other medications that are known to effect sleep
  • cannot have a current or previous major psychiatric disorder (other than insomnia) such as depression, schizophrenia, bipolar disorder, social anxiety, or another psychotic disorder.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00259311

  Show 22 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information Identifier: NCT00259311     History of Changes
Other Study ID Numbers: 9951
Study First Received: November 28, 2005
Last Updated: January 24, 2007

Additional relevant MeSH terms:
Sleep Initiation and Maintenance Disorders
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders processed this record on September 19, 2017